ZURICH (Reuters) - Roche Holding AG has halted a study of an experimental lung cancer drug because it failed to help patients with the disease, a blow for the drug which had been seen as a potential big seller as treatment options for the disease are limited.
Roche, the world's largest maker of cancer drugs, said an independent data monitoring committee had recommended the current study of the drug onartuzumab (MetMab) should be stopped because it wasn't shown to work in patients with non-small cell lung cancer when combined with the lung cancer drug Tarceva (erlotinib) in late-stage studies.
It said it was evaluating what the results of the study mean for the clinical program of MetMab and in the meantime was looking at options for lung cancer treatment.
"We remain committed to helping patients with lung cancer and are studying several investigational medicines in this disease," Roche Chief Medical Officer and Head of Global Product Development �Sandra Horning said in a statement on Monday.
MetMab was seen by some as a potential blockbuster because of the limited treatment options for lung cancers.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου